L
Laurent Poirot
Researcher at Royal Holloway, University of London
Publications - 80
Citations - 3208
Laurent Poirot is an academic researcher from Royal Holloway, University of London. The author has contributed to research in topics: Chimeric antigen receptor & Immunotherapy. The author has an hindex of 23, co-authored 66 publications receiving 2484 citations.
Papers
More filters
Journal ArticleDOI
Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
Laurent Poirot,Brian Philip,Cécile Schiffer-Mannioui,Diane Le Clerre,Isabelle Chion-Sotinel,Sophie Derniame,Pierrick Potrel,Cécile Bas,Laetitia Lemaire,Roman Galetto,Céline Lebuhotel,Justin Eyquem,Gordon Weng-Kit Cheung,Aymeric Duclert,Agnès Gouble,Sylvain Arnould,Karl S. Peggs,Martin Pule,Andrew M. Scharenberg,Julianne Smith +19 more
TL;DR: The applicability of TALEN-mediated genome editing to a scalable process enables the manufacturing of third-party CAR T-cell immunotherapies against arbitrary targets and can therefore be used in an "off-the-shelf" manner akin to other biologic immunopharmaceuticals.
Journal ArticleDOI
'Off-the-shelf' allogeneic CAR T cells: development and challenges.
TL;DR: This Review analyses the different sources of T cells and technological approaches to produce optimal allogeneic chimeric antigen receptor T cells with limited potential for graft-versus-host disease and increased persistence and describes the different technological approaches.
Journal ArticleDOI
Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy.
George H. Silva,Laurent Poirot,Roman Galetto,Julianne Smith,Guillermo Montoya,Philippe Duchateau,Frédéric Paques +6 more
TL;DR: These alternative approaches based on non-viral vectorization and/or targeted insertion aimed at achieving safer gene transfer are reviewed, with a special emphasis on megan nucleases, a family of naturally occurring rare-cutting endonucleases, and speculate on their current and future potential.
Patent
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
TL;DR: In this article, RNA-guided endonucleases, in particular Cas9/CRISPR system, were used to specifically target a selection of key genes in T-cells for immunotherapy.
Patent
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
Galetto Roman,Agnès Gouble,Grosse Stephanie,Cecile Mannioui,Laurent Poirot,Andrew M. Scharenberg,Julianne Smith +6 more
TL;DR: This article used rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells.